Virtus Fund Advisers’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Virtus Fund Advisers’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$321K	Buy	+8,547	New	+$373K	﹤0.01%	442

Other funds holding KDNY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Virtus Fund Advisers's KDNY Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2017: 8,547 shares worth $321K. The stake represents ﹤0.01% of the portfolio and ranks #442 among its holdings.

94 funds tracked by Wall St. Rank hold KDNY as of Q4 2017.

Virtus Fund Advisers held 8,547 shares of Chinook Therapeutics, Inc. Common Stock worth $321K as of Q4 2017.
Chinook Therapeutics, Inc. Common Stock was a new Virtus Fund Advisers position in Q4 2017.
Chinook Therapeutics, Inc. Common Stock made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #442 holding.
94 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.